CZ20003846A3 - Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva - Google Patents

Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva Download PDF

Info

Publication number
CZ20003846A3
CZ20003846A3 CZ20003846A CZ20003846A CZ20003846A3 CZ 20003846 A3 CZ20003846 A3 CZ 20003846A3 CZ 20003846 A CZ20003846 A CZ 20003846A CZ 20003846 A CZ20003846 A CZ 20003846A CZ 20003846 A3 CZ20003846 A3 CZ 20003846A3
Authority
CZ
Czechia
Prior art keywords
acetylglucosamine
carrier
composition
foam
nag
Prior art date
Application number
CZ20003846A
Other languages
Czech (cs)
English (en)
Inventor
Simon Murch
Ian W. French
Original Assignee
Glucogenics Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glucogenics Pharmaceuticals Inc. filed Critical Glucogenics Pharmaceuticals Inc.
Publication of CZ20003846A3 publication Critical patent/CZ20003846A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CZ20003846A 1998-04-17 1999-03-12 Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva CZ20003846A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002234936A CA2234936C (en) 1998-04-17 1998-04-17 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine

Publications (1)

Publication Number Publication Date
CZ20003846A3 true CZ20003846A3 (cs) 2002-03-13

Family

ID=4162337

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20003846A CZ20003846A3 (cs) 1998-04-17 1999-03-12 Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva

Country Status (8)

Country Link
EP (1) EP1071432A1 (no)
JP (1) JP2002512195A (no)
CA (1) CA2234936C (no)
CZ (1) CZ20003846A3 (no)
HU (1) HUP0101514A3 (no)
IL (1) IL139072A0 (no)
NO (1) NO20005223L (no)
PL (1) PL343634A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599605A (en) 2007-02-19 2013-11-29 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
KR101098581B1 (ko) * 2009-01-09 2011-12-26 서울대학교산학협력단 Ａｂｈ 항원을 이용한 염증질환 개선용 조성물
BR112012025844A2 (pt) 2010-04-15 2017-07-18 Marine Polymer Tech Inc uso de nanofibras snag
ES2712098T3 (es) 2011-04-15 2019-05-09 Marine Polymer Tech Inc Tratamiento de infecciones por VHS con nanofibras de poli-N-acetilglucosamina
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
ES2786312T3 (es) * 2014-11-26 2020-10-09 Evonik Operations Gmbh Composición farmacéutica o nutracéutica con resistencia contra la influencia de etanol
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Also Published As

Publication number Publication date
EP1071432A1 (en) 2001-01-31
HUP0101514A2 (hu) 2001-11-28
CA2234936A1 (en) 1999-10-17
NO20005223L (no) 2000-11-20
PL343634A1 (en) 2001-08-27
NO20005223D0 (no) 2000-10-17
HUP0101514A3 (en) 2003-07-28
JP2002512195A (ja) 2002-04-23
CA2234936C (en) 2004-06-29
IL139072A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
US6046179A (en) Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
US9782348B2 (en) Ingestible formulations for transient, noninvasive reduction of gastric volume
Chen et al. Local drug delivery systems for inflammatory diseases: Status quo, challenges, and opportunities
CZ295932B6 (cs) Prostředek pro podání léčiva pro lokalizované uvolňování léčiva v gastrointestinálním traktu zvířete a použití tohoto prostředku
RU2681930C2 (ru) Применение андрографолида в получении фармацевтического препарата для лечения воспалительного заболевания кишечника, микропеллета с андрографолидом для целенаправленной доставки в кишечник и способ ее получения
Leopold et al. Eudragit® E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD)
US10765709B2 (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
JP2015510928A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用方法
CZ20003846A3 (cs) Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva
JP5404406B2 (ja) 細胞外マトリクスの分解の阻害
JP2018039831A (ja) 排尿頻度を減少させるための医薬製剤およびその使用の方法
EP4157998A1 (en) Gel for use in gastrointestinal endoscopy and endodermal, epidermal, and other mucosal uses
JP6161734B2 (ja) グリコサミノグリカンを含有する医薬製剤
KR100375003B1 (ko) 배뇨장애 치료제
CN101432004A (zh) 用于控制的碳水化合物消化的联合治疗
Saffran Oral colon-specific drug delivery with emphasis on insulin
TWI446915B (zh) 玻尿酸混合物用於製造治療或預防黏膜相關病變或疾病之組成物的用途
CN112999146B (zh) 一种可注射黏附性水凝胶及其制备方法与应用
US20160151296A1 (en) Long delayed release laxative
Asteria et al. Multiple enterocolic perforations and their possible association with prolonged intake of nimesulide: report of two cases
Das Pharmacotherapy of inflammatory bowel disease
Kulkarni et al. CODES TECHNOLOGY: A NOVEL APPROACH FOR COLON TARGET-A REVIEW ARTICLE
WO2000006132A2 (en) Pharmaceutical formulations comprising beclomethasone dipropionate for the treatment of inflammatory bowel disease
Bell Drugs used in the management of gallstones
Kiran et al. COLO TARGETED DRUG DELIVERY SYSTEMS: OVEL APPROACHES